The substitution of vonoprazan, a novel potassium-competitive acid blocker that provides reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase, for PPIs has shown promising results, however remains to be tested outside Asia. [4] [5] [6] [7] Quadruple therapy is gaining in popularity particularly in areas with increasing resistance to standard triple therapy. 8, 9 Tailored, culture-based treatment seems a logical choice and has significant success. 10 However, there is an expense and delay involved, which limits its universal use at present.
Levofloxacin remains one of the most favored second-line therapies; however, bismuth, when available, is an increasingly successful option. Sequential therapy remains in use in areas of high resistance, but may prove challenging in terms of compliance, and is no longer recommended. 11 Three-in-one formulations of bismuth quadruple therapy (BQT) may improve compliance. 12, 13 Probiotics appear to have some effect on H. pylori eradication, as their addition likely improves compliance by reducing the side effects of antibiotics. 14 For example, several meta-analyses reported a gain of 10%-14% in the cure rate from the addition of a probiotic to traditional therapy compared to placebo. [14] [15] [16] [17] The European Registry on H. pylori management, supported by the European Helicobacter and Microbiota Study Group (EHMSG), is an exciting new endeavor which represents an audit process to ensure that clinical practice is aligned with best standards of care.
There are now over 21 000 entries from 27 European countries and DOI: 10.1111/hel.12519
the Registry promises to provide invaluable information regarding H. pylori treatment across Europe. 18 
| S TANDARD TRIPLE THER APY
High-dose acid suppression and treatment duration of a minimum of 10 days offer the best conditions for success with triple therapy.
Several studies in the past year have demonstrated the utility of standard triple therapy in low resistance areas (<20% resistance to clarithromycin). 19 A retrospective study from the New York metropolitan area reported a cumulative eradication rate of 86% with 10- Quadruple therapy, comprised of standard triple therapy with the addition of rifaximin (a nonabsorbable antibiotic), had poor results with eradication rates of 61% in Spain. 23 Metronidazole continues to underperform in triple therapy, with eradication rates of 64% in metronidazole-naive patients. 24 High-dose metronidazole does enhance eradication rates however in areas of high metronidazole resistance, 25 demonstrating that in vitro resistance of metronidazole does not always correlate to in vivo failure.
Resistance to the commonly used antibiotics is increasing in certain areas over time, as demonstrated by a retrospective review from the Netherlands which reported increasing resistance rates for clarithromycin (9.8%-18.1%), metronidazole (20.7%-23.2%), and ampicillin (6.3%-10%) over 10 years. 26 A 10-year follow-up study from
Italy showed suboptimal eradication rates using amoxicillin and metronidazole, which had not changed significantly (73.5% vs 69.2%) in the past decade. 27 A further study from Italy suggested that while resistance to the most frequently used antibiotics had increased, it had likely plateaued over the past number of years. 28 The first systematic review of primary antibiotic resistance in the Asia-Pacific region reported mean resistance rates of 17% for clarithromycin, 18%
for levofloxacin, and 44% for metronidazole. There was, however, significant heterogeneity in resistance rates across different countries in the region. 29 There would appear to be a maximal acid-suppressive effect with PPI bid dosing in triple therapy. Eradication rates with PPI tid dosing compared to PPI bid dosing in standard triple therapy were not improved. 30 Reports of increasing resistance to the components of standard triple therapy have led to the development of alternative treatment regimens and a general shift away from the traditional treatment protocols, particularly in areas with high antibiotic resistance. 34 The addition of bismuth to levofloxacin-based triple therapy, however, in areas with low levofloxacin resistance does not confer any further benefit. 35 A retrospective study assessing the utility of a moxifloxacinbased triple therapy reported eradication rates of 80% following hybrid therapy failure. 36 Quinolone-based rescue therapies are more successful in bismuth-containing quadruple therapies, with longer duration (10-14 days) than 7-day treatment. 37 A meta-analysis found levofloxacin-based triple therapy superior to bismuth-based quadruple therapy in Europe but equivalent in Asia when used for 10 days.
| FLUOROQUINOLONE S
Compliance was also superior and side effects lesser. 38 The choice of fluoroquinolone to select has become an important question.
The addition of ofloxacin to standard triple therapy has been shown to augment eradication rates, 39 while gemifloxacin was inferior to clarithromycin-based therapies. 40 A review of levofloxacin-based third-line therapy over the past decade in Korea found pooled eradication rates of 71.6% throughout the decade, suggesting no increase in resistance rates over the past decade. 41 A 10-day triple therapy containing ilaprazole, levofloxacin, and amoxicillin reported good results, with an eradication rate of 88.8%. 42 
| B IS MUTH
Bismuth salts exert direct bactericidal effect on H. pylori in a number of ways: by forming complexes in the bacterial wall and in the periplasmic space and by adherence of the bacteria to the gastric mucosa. Bismuth also aids ulcer healing by increasing mucosal protective factors such as prostaglandin, epidermal growth factor, and bicarbonate secretion. 43 In areas with multiresistant strains of H. pylori and high rates of antibiotic resistance, bismuth rescue therapy is an effective treatment option, with eradication rates as high as 97.6%. 8, 13, 44 BQT is commonly recommended in treatment guidelines as a rescue therapy 2 and as first-line therapy in areas of high resistance. The three-in-one capsule (Pylera ® ) has proven a popular treatment option for patients which may improve compliance. BQT has been shown to be effective as both a firstline and rescue therapy option. 8, 12, [45] [46] [47] [48] A Chinese randomized controlled trial reported convincing superiority for 10-day quadruple bismuth-based therapy over 10-day standard triple therapy (92.3% vs 63.2%). 9 Modifications to the standard BQT have also been studied this past year. A trial of 7-day concomitant quintuple therapy containing bismuth demonstrated effective eradication rates but with increased side effects. 49 The addition of bismuth to standard 7-day triple therapy did not substantially increase the eradication rate in one study. 50 A comparison of levofloxacin-containing triple therapy with levofloxacin-containing BQT and standard BQT from Turkey found bismuth-containing regimens to be superior. 51 An American study found modified dual therapy consisting of higher doses of PPI reached comparative eradication rates with BQT, without significant adverse effects. 52 Safety of new medication is always a concern. One study assessing vonoprazan triple therapy in children found adverse effects (rash/GI disturbance) in 21.1%. 59 Vonoprazan represents one option to combat decreasing eradication rates for clarithromycin-based triple therapy;
| VONOPR A Z AN
however, there is concern this may not be adequate for countries with higher rates of clarithromycin resistance. 60 An important caveat to these promising results is that in many of the head-to-head trials,
vonoprazan was compared to single dosing PPI which does not reflect the optimum use of this treatment. 
| CULTURE-G U IDED TRE ATMENT
Culture-guided treatment has been recommended in the Maastricht patterns are increasingly employed to guide the selection of antibiotics, particularly in regions with high resistance rates. Antibiotic resistance varies significantly across the globe (Table 2) . A prospective Greek study enrolled 51 patients for genotypic resistance-guided 7-day triple therapy. Genotyping of clarithromycin, levofloxacin, and rifabutin was performed. Following tailored triple therapy, the pooled eradication rate was 97.8%. There was no significant difference in eradication rates between treatment-naive and treatmentexperienced groups. 61 This, however, is at odds with a Spanish study which found significantly higher eradication rates (83% vs 33%) in culture-guided therapy in treatment-naïve patients. 10 An Italian study comparing sequential and bismuth-based therapy did not find that the pattern of bacterial resistance significantly affected eradication rates. Dual resistance to clarithromycin and amoxicillin did, however, lower eradication rates in both treatment strategies. 62 Susceptibility-based therapy is especially important to guide tailored treatment after failure of standard empiric thera-
pies. An American retrospective cohort study analyzed 49 patients who had failed at least three empiric treatment regimens. Culturepositive H. pylori was confirmed in 82% (n = 42), of whom 60%
(n = 24) achieved successful eradication following tailored treatment, thus highlighting the difficulties in achieving eradication even in the setting of AST. 63 Indeed, third-line culture-guided eradication therapy often fails.
Multidrug (>3) resistance rates have been found in 15%-31% of patients undergoing third-line therapy. 10 Age >50 years was the only discerning factor associated with resistance to three or more antibiotics, most likely related to lifetime exposure. 64 However, cultureguided first-line treatment is seldom.
| PROB IOTIC S
The interest in probiotic therapy as an adjunct to eradication therapy has certainly increased over the past year with the number of publications rising significantly. As the effective treatment duration increases, there is a concern regarding antimicrobial side effects. In one recent study, the addition of a probiotic was shown to reduce the frequency of adverse events from 28.2% in the nonprobiotic group to 12.2%.
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A meta-analysis reported that the addition of a probiotic to bismuth-based quadruple therapy increases the eradication rate by approximately 10%. 14 A systematic review assessed the efficacy of probiotics as monotherapy. While probiotics were found to be superior to placebo, the pooled eradication rate from the 11 included studies was only 14%. 66 One study evaluated the anti-H. pylori activity of seven Lactobacillus delbrueckii subsp. bulgaricus (GLB) strains. 67 The GLB strains were found to produce heat-stable bacteriocin-like inhibitory substances that had a strong anti-H. pylori activity, ren- H. pylori eradication in a double-blind placebo-controlled randomized 2-site study. The cure rates per protocol were 3/24 (12.5%; 95% CI 2.6%-32%) with L. reuteri vs 1/24 (4.1%) with placebo. 17 One study aimed to identify the best probiotic supplementation in triple therapy for a pediatric population. In total, 29 trials were reviewed. Lactobacillus casei was identified as the best probiotic for H. pylori eradication rates and multistrain of Lactobacillus acidophilus and Lactobacillus rhamnosus for total side effects. Another study suggested the combination of Bacillus mesentericus, Clostridium butyricum, and Streptococcus faecalis as the optimal probiotic regime for reducing side effects and improving eradication rates when supplementing 14-day triple therapy. 68 Current meta-analyses suggest that probiotics as an adjunctive therapy increase the cure rate by approximately 10%-14%. [14] [15] [16] [17] In addition, probiotics are likely to improve compliance and therefore improve eradication rates of triple therapy. However, the potential benefit of adding probiotics to more recent and effective combinations (such as concomitant or BQT regimens) has yet to be proven.
| S EQUENTIAL AND CON COMITANT THER APY
Most clinical guidelines recommend BQT as rescue treatment for H. pylori eradication failure. However, high cost, side effects, and low compliance rates are major drawbacks to its routine use. Ten-day sequential therapy is more efficient than BQT (Pylera ® ) in terms of H. pylori eradication in high resistance areas. 69 Neither an extension to the duration of sequential treatment to 14 days nor the addition of bismuth improved eradication rates. 70 In Korea, where high levels of clarithromycin resistance have been reported, 10-day concomitant therapy achieved eradication rates in excess of 95% in per protocol analysis 71 and proved superior to sequential therapy in terms of efficacy. 72 A systematic review and meta-analysis compared the efficacy and safety of concomitant and sequential therapy. In this review, the efficacy of concomitant therapy was found to be duration dependent, with 10-day concomitant therapy being the most efficacious therapy and superior to 10-day sequential therapy. Concomitant therapy also showed superior efficacy for metronidazole-resistant strains and metronidazole plus clarithromycin-resistant strains. 73 A study from Israel suggested better compliance and fewer adverse effects with sequential treatment when used as a second-line regimen, which they found noninferior to bismuth-based quadruple therapy.
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A 5-year prospective review in Italy assessed antimicrobial resistance to clarithromycin, metronidazole, and levofloxacin before giving 10-day sequential therapy as first-line therapy. Even in patients with dual resistance, 10-day sequential therapy was 83.1% effective in treating the underlying H. pylori infection. 11 A Turkish study highlighted the role for 5 + 5 clarithromycin-based sequential therapies in areas with low clarithromycin resistance rates, which was found to be superior to 14-day triple therapy and BQT. 75 
| HYB RID THER APY
Hybrid therapy initially emerged as a promising alternative approach to H. pylori eradication, particularly in areas with high antibiotic resistance rates. In the past year, however, interest in this treatment paradigm waned. One study assessed hybrid therapy consisting of 14-day therapy with a PPI and amoxicillin, with the addition of clarithromycin and metronidazole for the final 7 days, and demonstrated eradication rates >90% even in the presence of significant antibiotic resistance. 19 Dual antibiotic resistance, however, significantly reduced eradication rates. Another study compared hybrid therapy with sequential therapy in an Indian cohort and reported significantly higher eradication rates (93% vs 81.5%) and comparable compliance rates and side effects. 76 
| FAC TOR S OF TRE ATMENT FAILURE
A number of studies have sought to identify factors associated with treatment failure. A retrospective study from Spain suggests previous use of macrolides correlates with a low H. pylori eradication rate with triple and concomitant clarithromycin-containing regimens. 77 Repeated use of previously failed treatment combinations also contributes to poor eradication rates, 78 highlighting the importance of efficient documentation of treatment histories. Treatment failure occurred more frequently in patients with 25-OH vitamin D deficiency, 79 whereas supplementing eradication therapy with vitamin C and E has no effect. 80 A Japanese study found lower eradication rates with standard triple therapy in younger cohorts, perhaps reflecting poorer compliance. A study from Africa suggests that the methanol extract of Bryophyllum pinnatum, a plant known for its antioxidant properties, could inhibit H. pylori growth, and may also act as an antioxidant to protect gastric mucosa against reactive oxygen species. 84 A study from Iran demonstrated reduced endoscopic scores of inflammation and increased H. pylori eradication rates with the addition of curcumin (a turmeric extract) to standard triple therapy. 85 An
Egyptian group evaluated eradication rates with nitazoxanide, an
anti-infective drug with demonstrated activity against protozoa and 
| G UIDELINE S
The past year has seen several national and society guidelines updated. The fifth Chinese national consensus report, 91 a Catalan position paper, 92 the first Irish consensus statements, 93 local management in Piedmont (Italy), 94 and updated American College of Gastroenterology clinical guidelines 95 were all published in the past year. The proliferation of national and regional guidelines reflects the emphasis Maastricht V guidelines have put on the importance of local resistance patterns. Treatment options based on local resistance patterns taking antibiotic susceptibility into account remain the goal. 2 
| REG IS TRIE S
The European Registry on H. pylori management, supported by the EHMSG, is an exciting new endeavor which represents an audit process to ensure clinical practice is aligned with best standards of care. There are now over 21 000 entries from 27 participating European countries and the Registry promises to provide invaluable information regarding H. pylori treatment across Europe. 18 The Registry has received international recognition and was awarded the National Scholar Award by the United European
Gastroenterology. This year, published data from the Registry regarding Slovenia demonstrate low resistance to clarithromycin, where triple therapy with PPI plus two antibiotics reaches eradication rates >85%. 96 
| CON CLUS ION
The treatment of H. pylori remains a much studied and debated topic. Antibiotic resistance is a stumbling block to current therapies and prevents universal consensus on best treatment options. As treatments remain complex, compliance is an ongoing issue. Culturebased treatment would overcome many of these obstacles and appears logical, but is not currently universally applied.
D I S CLOS U R E S O F I NTE R E S T S
The authors have no interests to disclose.
R E FE R E N C E S

